Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Wild-Type Advanced Non-Small Cell Lung Carcer

The major proportion of advanced non-small cell lung carcer does not contain activating mutations in the epidermal growth factor receptor （EGFR）, which is called EGFR wild type （WT）. Despite EGFR-WT patients who lack the sensitivity of EGFR tyrosine kinase inhibitors （TKI）, there are some evidences demonstrating that some EGFR-WT patients can get benefit from EGFR-TKI. No prognostic biomarkers can predict outcomes of EGFR-WT treated by TKI so far.